Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Molecules ; 27(11)2022 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-35684445

RESUMO

The most common primary malignant brain tumors in adults are gliomas. Glioblastoma is the most prevalent and aggressive tumor subtype of glioma. Current standards for the treatment of glioblastoma include a combination of surgical, radiation, and drug therapy methods. The drug therapy currently includes temozolomide (TMZ), an alkylating agent, and bevacizumab, a recombinant monoclonal IgG1 antibody that selectively binds to and inhibits the biological activity of vascular endothelial growth factor. Supplementation of glioblastoma radiation therapy with TMZ increased patient survival from 12.1 to 14.6 months. The specificity of TMZ effect on brain tumors is largely determined by special aspects of its pharmacokinetics. TMZ is an orally bioavailable prodrug, which is well absorbed from the gastrointestinal tract and is converted to its active alkylating metabolite 5-(3-methyl triazen-1-yl)imidazole-4-carbozamide (MTIC) spontaneously in physiological condition that does not require hepatic involvement. MTIC produced in the plasma is not able to cross the BBB and is formed locally in the brain. A promising way to increase the effectiveness of TMZ chemotherapy for glioblastoma is to prevent its hydrolysis in peripheral tissues and thereby increase the drug concentration in the brain that nanoscale delivery systems can provide. The review discusses possible ways to increase the efficacy of TMZ using nanocarriers.


Assuntos
Neoplasias Encefálicas , Glioblastoma , Glioma , Adulto , Anticorpos Monoclonais/uso terapêutico , Antineoplásicos Alquilantes/farmacologia , Neoplasias Encefálicas/patologia , Linhagem Celular Tumoral , Glioblastoma/tratamento farmacológico , Glioblastoma/metabolismo , Glioma/tratamento farmacológico , Humanos , Temozolomida/farmacologia , Fator A de Crescimento do Endotélio Vascular
2.
Ann Med Surg (Lond) ; 61: 13-15, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33363720

RESUMO

Hepatic cystadenoma is an urgent problem due to the high risk of malignant transformation. There are both radical and minimally invasive methods of treatment. We present a clinical case describing the successful use of microwave ablation (MWA) in a 72-year-old woman with hepatic cystadenoma. The patient was admitted to the clinic with abdominal discomfort, dull pain in the right hypochondrium, and weight loss of 10 kg during the previous year. The patient had a past medical history of liver cyst in segment VII. Ultrasound scanning, computed tomography (CT) of abdominal organs detected an increase in the size of the cyst, heterogeneity of its structure; the contrast enhancement was noted in the cyst wall. We suspected hepatic cystadenoma in segment VII and performed cyst puncture under ultrasound control - the obtained fluid revealed the presence of cylindrical epithelial cells, mucin, and macrophages in large quantities, high telomerase activity, CA 19-9 levels were greater than 1000 U/mL. Surgery was accomplished using the MWA catheter. Biological and cytological examination of the fluid confirmed the presence of signs of liver cystadenoma with a high malignancy risk. On the 2nd day after surgery ultrasound imaging of the abdomen revealed the residual cavity of 2 × 1 cm in segment VII. The patient was discharged with recommendations to conduct ultrasound examinations every six months. The control CT scan in 2020 showed no focal or cystic formations in the liver. In what way, MWA under control of ultrasound is a promising method of biliary cystadenoma treatment with high malignancy risk.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA